DalsnaFinance

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Markets PR Newswire By PR Newswire 03 Jun 2026 07:11 1 min read
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

MUMBAI, India and NAPLES, Fla., June 3, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the United States Food and Drug...

MUMBAI, India and NAPLES, Fla., June 3, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the United States Food and Drug...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.